Kornimate/medical-research-clean huggingface dataset:
one-year outcome after prehospital intubation

Conditions: One-year Outcome After Prehospital Intubation

Summary: the primary aim of this study was to describe the long-term outcome of critically ill or severely injured patients not in cardiac arrest treated by an ems physician.

the aim of helicopter emergency medical services (hems) is to supplement ground ems units in the care of prehospital patients. the need for advanced airway management in critical out-of-hospital patients can be considered as one indicator of the severity of the patient's condition. a recent european initiative suggested advanced airway management to be included in the top five research priorities for physician-provided prehospital care.to our knowledge, no previous studies describe the long-term outcome of critical prehospital patients treated by an ems physician. the primary aim of this study was to describe the long-term outcome of critically ill or severely injured patients not in cardiac arrest treated by an ems physician. our secondary aims were to determine the indications and causes for ems physician performed prehospital endotracheal intubation.

Eligibility criteria:
inclusion criteria: * all non-cardiac arrest patients. exclusion criteria: * patients with a known need for personal assistance in activities of daily life prior to the incident leading to prehospital intubation (outcome evaluation). * patients intubated by ems before hems arrival. * death on scene or during transportation.

Keywords: prehospital emergency care (mesh) emergency medical services (mesh) helicopter emergency medical service, critical care (mesh) airway management (mesh) endotracheal intubation (mesh) patient outcome
ursodeoxycholic acid and cholestasis of pregnancy

Conditions: Intrahepatic Cholestasis of Pregnancy

Summary: the study is a multicenter randomized double blind placebo controlled trial. the study will be conducted on pregnant women with a diagnosis of intrahepatic cholestasis of pregnancy (icp) in third level hospitals (that are also academic hospitals). pregnant women at the time of icp diagnosis will be randomized in two groups: group 1 - will receive placebo and obstetrical monitoring until delivery group 2 - will receive udca at the dose of 20 mg/kg/day and obstetrical monitoring until delivery. the hypotheses are that udca treatment will be superior to placebo and effective in: reducing the rate of prematurity; improving maternal biochemical parameters and symptoms.


Eligibility criteria:
inclusion criteria: * pregnant state (after week 20 of gestation) * total serum ba elevation (\>10 micromol/l) * transaminases elevation (alt\>40 ui/l and ast\>37 ui/l) * occurrence of pruritus * informed consent signed exclusion criteria: * infectious diseases (hbv, hdv, hcv related liver disease, ebv, cmv, hiv infection) * dermatologic diseases * metabolic diseases (including alcohol abuse) * other causes of cholestasis (i.e. pbc; psc) * autoimmune liver disease * obstructive biliary diseases * drug related pathologies * known or suspected hyper-sensibility to the drug or the pharmacological class under study * serious clinical conditions that, according to the judgment of the investigator, contraindicate the participation to the study (heart, kidney and liver disease) * use of cholestyramine * patients not able or not willing to follow the procedures of the protocol * patients not signing the informed consent * onset of icp during of after the 36th week of pregnancy

Keywords: cholestasis pregnancy ursodeoxycholic acid icp
addressing disparities in colorectal cancer screening in black and underserved phoenix communities

Conditions: Colorectal Carcinoma

Summary: this clinical trial studies disparities involving colorectal cancer prevention and screening in black and underserved communities in the phoenix metropolitan area. the black community is disproportionately impacted by colorectal cancer, with the highest rate of any racial/ethnic group in the united states. there are complex reasons behind these disparities, largely related to socioeconomic factors and healthcare access. providing access to free, home-based fecal immunochemical testing (fit), colorectal screening education, and appropriate follow-up to predominantly black community-based organizations and underserved communities may help to close this gap.

primary objectives: i. to evaluate patient navigation to address colorectal cancer disparities seen in people of color, minority populations, and establish an ongoing colorectal cancer screening outreach program for this community in phoenix. outline: participants receive free fit tests in conjunction with education on colorectal cancer screening. participants undergo self-collect fit and mail the sample to mayo clinic lab for processing. participants also complete a questionnaire about colorectal cancer screening and healthcare. participants receive fit test results through mayo clinic nursing support and participants with a positive test are followed up by a patient navigator to discuss next steps and consultation with a gastroenterologist to review their results. after completion of screening, participants with a positive fit test are followed up at 2 and 4 weeks after initial outreach to assure participants have received adequate follow up.

Eligibility criteria:
inclusion criteria: * age 45 years of age or older * no prior history of colorectal cancer or colon polyps * no first-degree family history of colorectal cancer who were diagnosed under age 60 * no current gastrointestinal (gi) or rectal symptoms (such as rectal bleeding) * have not undergone a colonoscopy in the last 5 years * have not had a fecal immunochemical test (fit) test within the last year * participants that attend 4 predominantly african american churches within the phoenix community and extend the study opportunity as feasible to other underserved communities in the phoenix metro area
low-risk chest pain echo study

Conditions: Chest Pain

Summary: pilot study to assess if a bedside point-of-care echocardiogram performed on emergency department patients identified as low-risk chest pain prior to discharge significantly changes patient disposition or follow up instructions.


Eligibility criteria:
inclusion criteria: * adults presenting to the emergency department with an isolated chief complaint of chest pain with a heart score of 3 or less * emergency physician of record has decided to discharge this patient from the emergency department exclusion criteria: * patients who are unable to consent for themselves * history of cardiac transplant or lvad * pediatric patients * patients presenting with multiple complaints in addition to chest pain * echocardiogram already performed on patient during usual care * patients with another non-cardiac admittable diagnosis * heart score greater than or equal to 4
long-term respiratory complications in infants with perinatal covid-19

Conditions: COVID-19; Infant, Newborn, Diseases; Respiratory Function Tests

Summary: study outcomes and endpoints: * primary outcome: to assess clinical characteristics of infants with confirmed covid-19 infection at birth and to evaluate long-term respiratory consequences of neonatal covid-19 infection. * secondary outcome: to evaluate the prevalence and natural history of lung function impairment among infants with confirmed covid-19 compared to infants with no history of covid-19. to this end, infants will undergo pulmonary function testing (pft) with the exhalyzer d device (eco medics, switzerland).

in this prospective, observational longitudinal study, infants will undergo clinical and growth assessment at 6 and 12 months' follow-up. respiratory complications, such as wheezing, infections, chronic cough will be recorded along with hospital admissions and drug prescription or use. infants will undergo pft with the infants in the supine position, during quiet, natural sleep, according to american thoracic society/european respiratory society recommendations with measurement of lung volumes, flow, functional residual capacity, time to peak tidal expiratory flow/expiratory time ratio (tptef/te)10. lung ultrasound will be performed to rule out lung abnormalities. after allowing adaptation to the mask, the investigators will record tidal breathing, flow volume loops for \>2 minutes or \>20 artifact-free breaths. using commercially available software (spiroware, ecomedics), the investigators will extract tidal breathing parameters: ratio of time to reach peak tidal expiratory flow to expiratory time (tptef/te), tidal volume (vt), and respiratory rate (rr). tptef/te is a reproducible and reliable marker of airway obstruction, can detect severe expiratory airway obstruction in infants with respiratory complaints and is associated with subsequent wheezing in infancy. appropriate statistical methods will be used to describe clinical characteristics of patients and compare groups (t-test, mann-whitney test, chi-squared test, multivariate analysis, mixed models depending on data distribution - evaluated with shapiro-wilk test - and data characteristics).

Eligibility criteria:
inclusion criteria: * term infants; * informed consent; * history of perinatal covid-19 (confirmed by nasopharyngeal swab tests, study group) exclusion criteria: * congenital malformations (particularly airway malformations); * lack of informed consent
gender heterogeneity in the influencing factors for cerebral microbleeds in acute ischemic stroke patients

Conditions: Acute Ischemic Stroke

Summary: the investigators continuously collected data from 482 ais inpatients at the neurology department of hebei general hospital. both demographic and clinical data were collected from the study subjects. different head magnetic resonance imaging sequences were used to assess the subjects' cmbs, white matter lesions, and old lacunar infarcts (li). various statistical methods, including the t-test, χ2 test, and logistic regression, were used to analyze the gender heterogeneity of the influencing factors for cmbs in ais patients.


Eligibility criteria:
inclusion criteria: * aged 18 years and older * must meet the diagnostic criteria for ais as presented in the chinese guidelines for diagnosis and treatment of acute ischemic stroke 2014 * must be in good physical condition and have the ability to cooperate with mri examinations * must have underwent swi exclusion criteria: * mri contraindications present, such as cardiac pacemaker, cardiac stents, or metal implants * head mri or carotid artery ultrasound suggests the presence of severe stenosis or occlusion in the intracranial or extracranial segments of the cerebral arteries * severe comorbid diseases, such as cardiac, pulmonary, hepatic, and renal insufficiencies

Keywords: acute ischemic stroke cerebral microbleeds influencing factors gender heterogeneity
clinicopathological characteristics and prognosis analysis of stage ib non-small cell lung cancer

Conditions: Stage IB Non-Small Cell Lung Carcinoma

Summary: the goal of this observation study is to learn about clinicopathological characteristics and prognostic factors of stage ib nsclc. the main question it aims to answer is wheather there is relationship between newly proposed clinicopathological features and the prognosis of stage ib nsclc .the postoperative pathological and follow-up information of participants will be used for subsequent analysis.

a total of 971 nsclc patients with pathological stage ib resected by surgery (r0) from january 2016 to december 2020 at zhongshan hospital of fudan university were reviewed. the primary endpoint is rfs (recurrence-free survival) and os (overall survival) is the secondary endpoint. the baseline characteristics of the patients were obtained statistically, and factors affecting the prognosis of patients with stage ib nsclc were analyzed using survival analysis and cox proportional hazard models. the characteristics of the patients include pathological type, stas, ggo, gene mutation, and postoperative adjuvant chemotherapy.

Eligibility criteria:
inclusion criteria: * it was confirmed by histopathology as primary non-small cell lung cancer, and the pathological type was lusc or luad; * according to the 8th edition of tnm clinical staging standards, it is determined as ib stage * no treatment was performed for the primary lesion of lung cancer before surgery; * no history of other malignant tumors before surgery; * detailed clinical and pathological information, complete survival data, and no missing follow-up data. exclusion criteria: * the postoperative histopathological types include non-scale and non adenocarcinoma, such as lung adenosquamous cell carcinoma, large cell lung cancer, or lung sarcomatoid carcinoma; * multiple lesion staging surgery; * history of merging with other malignant tumors * having preoperative treatment; * missing follow-up information.
the role of concurrent chemotherapy for lower risk locally advanced nasopharyngeal carcinoma(npc) in the era of imrt

Conditions: Nasopharyngeal Carcinoma

Summary: the purpose of this study is to verify that simultaneous integrated boost imrt (sib-imrt) alone is non-inferior to sib-imrt combined with concurrent chemotherapy for low-risk locally advanced nasopharyngeal carcinoma.

* there were several randomized clinical trials confirmed that concurrent chemoradiotherapy (ccrt) is superior to radiotherapy (rt)alone for locally advanced npc, most of the patients in the trials were treated with conventional radiotherapy technique. * as the new technique of imrt used more and more in the clinical practice, the role of concurrent chemoradiotherapy (ccrt) seems blurred, in two of hongkong phaseiii studies(npc9901/9902), half of the patients were treated by 3-dimensional conformal radiotherapy (3dcrt)/imrt,the results showed that there were no significant different in terms of overall survival between rt alone and ccrt groups. furthermore, several large sample size retrospective studies from china, showed that there were no advantage of ccrt over rt alone when treated by sib-imrt. * in an analysis of who will benefit from ccrt,( lin, et.al, ijrobp,2004; 60:156-164), the author divided the locally advanced npc patients into two groups, with the high-risk group defined as patients met at least one of following criteria: nodal size \>6 cm, (2) supraclavicular node metastasesn3, t4n2 and multiple neck node metastases with 1 node \>4cm. * based on these information, we hypothesize that, for low-risk locally advanced npc patients, there may no need ccrt under sib-imrt treatment.

Eligibility criteria:
inclusion criteria: * histopathological proven non-keratin nasopharyngeal carcinoma * ajcc 7th edition stage iii/ivm0, without any one of following factors: node size \>6cm;supraclavicular metastasis node; t4n2; multiple neck node metastases with 1 node \>4 cm * life expectancy≥6 months * adequate renal function, defined as follows: serum creatinine \< 2 x institutional upper limit of normal(uln) within 2 weeks prior to registration or creatinine clearance rate (ccr) ≥ 50 ml/min within 2 weeks prior to registration determined by 24- hour collection or estimated by cockcroft-gault formula: ccr male = \[(140 - age) x (wt in kg)\] \[(serum cr mg/dl) x (72)\] ccr female = 0.85 x (ccrmale) * the following assessments are required within 2 weeks prior to the start of registration: na, k, cl, glucose, ca, mg, and albumin exclusion criteria: * prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated \< 3 years ago * prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * severe, active co-morbidity * treatment planning does not meet the requirement of prescription dose.

Keywords: nasopharyngeal carcinoma current chemotherapy intensity-modulated radiotherapy low-risk
non- clinical coagulation activation during hemodialysis

Conditions: Kidney Diseases; End Stage Renal Disease; Hemodialysis Complication

Summary: every patient included in the study will undergo 1 conventional hemodialysis treatment, ie 1 study visit. during the conventional hemodialysis treatment lasting 4 hours, 2 blood samples will be taken at different time points (5 minutes after dialysis start and 240 minutes after dialysis = at the end of the dialysis session) to evaluate coagulation activation (tat, pf1+2). hemodialysis session parameters (arterial and venous pressure, tmp, ocm, bvm and prefilter pressure) will be noted at different time points (t5, t30, t60, t120, t180, t240). after discontinuation of the dialysis session, total cell volume will be measured using the renatron ii system® and the number of open fibers will be determined using micro-ct scanning.


Eligibility criteria:
inclusion criteria: * ≥ 18 years of age. * patients able and agree to provide signed informed consent. exclusion criteria: * known allergy for polysulphone dialysis membrane. * use of vitamin k antagonists or novel oral anticoagulant therapy. * use of chronic heparin treatment, ufh or lmwh.

Keywords: clotting coagulation
gene therapy for cardiomyopathy associated with friedreich's ataxia

Conditions: Friedreich Ataxia; Cardiomyopathy, Secondary

Summary: this is a phase 1/2, open-label, dose-ascending, multicenter study of the safety and efficacy of lx2006 for participants who have friedreich's ataxia with evidence of cardiomyopathy. the study will evaluate up to three doses of single administration of lx2006 (aavrh.10hfxn), an adeno-associated virus (aav) gene therapy designed to intravenously deliver the human frataxin (hfxn) gene to cardiac cells over a 52-week period. long-term safety and efficacy will be evaluated for an additional 4-years for a total of 5-years post lx2006 treatment.

friedreich's ataxia (fa) is a rare, autosomal recessive disease caused by a mutation in the autosomal frataxin (fxn) gene. progressive cardiomyopathy with cardiac hypertrophy and fibrosis is observed in most individuals with fa. the disease is more severe in those with earlier onset. presently, there is no therapy that alters the progression of cardiomyopathy in fa, which is responsible for 59% of fa-related deaths. the primary objective of this dose escalation study is to assess the safety and tolerability of three ascending doses of lx2006 in patients with fa-associated cardiomyopathy. lx2006 is designed to restore hfxn levels in order to improve mitochondrial function. assessments of cardiac function, biomarkers and other preliminary efficacy endpoints are also included in this study.

Eligibility criteria:
inclusion criteria: * confirmed genetic diagnosis of fa, with onset being before 25 years of age * protocol specified ranges for antibodies * protocol specified measures of fa cardiomyopathy exclusion criteria: * protocol specified ranges for left ventricular ejection fraction (lvef) as measured by cardiac echo * uncontrolled diabetes * abnormal liver function * active infection of any type, including hepatitis virus (a, b or c) or human immunodeficiency virus (hiv-1 and hiv-2) * contraindication to cardiac mri * contraindications to cardiac biopsies * participants who are receiving systemic corticosteroids or other immunosuppressive medications * history of significant coronary artery disease or any structural heart or vascular disease other than fa cardiomyopathy * presence of clinically significant, hemodynamically unstable arrhythmias, requiring physician intervention * presence of clinically significant abnormalities as determined by the investigator, other than ecg abnormalities related to fa * uncontrolled psychiatric disease other inclusion/exclusion criteria to be applied as per protocol.

Keywords: friedreich's ataxia cardiomyopathy fa gene therapy fxn gene frataxin gene lx2006
dorsovolar kinesiotape in carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome Treatment

Summary: this study aimed to compare the short- and medium-term efficacy of dorso-volar kinesiotape (kt) added to home exercises (he) with sham-kt and he alone in the treatment of mild or moderate carpal tunnel syndrome (cts) in terms of pain, symptom severity, function, grip strength, and electrophysiological parameters.


Eligibility criteria:
inclusion criteria: * pain or numbness radiating to the palm for at least 6 weeks, * at least one positive tinel's, phalen's, or carpal compression test on physical examination, and * mild/moderate cts on emg examination. exclusion criteria: * metabolic disease (diabetes, rheumatoid arthritis, thyroid disease), * systemic or malignant disease, history of trauma, fracture or surgery to the wrist, * physical therapy programs, surgical procedures, injections or kt applications to the wrist for cts treatment in the past year, * severe thenar atrophy, * c6-c7 radiculopathy among cts differential diagnoses, * cervical spondylosis, thoracic outlet syndrome, entrapment of the median nerve above the wrist, * polyneuropathy or traumatic injury to the median nerve, * rashes or open wounds on the skin of the wrist and forearm that could prevent treatment with kinesiology taping

Keywords: carpal tunnel syndromes kinesiotape electromyography median neuropathy muscle strength pain